(Bloomberg)– Eli Lilly & &Co (LLY) authorized a program to redeem as high as $15 billion of its very own shares in the middle of quick development sustained partly by the hit weight-loss medication Zepbound.
Most Read from Bloomberg
The firm likewise increased its quarterly returns 15%, according to a declarationMonday The shares climbed as high as 1.3% in late trading after the United States markets shut.
The share repurchases might be made every so often at administration’s discernment, Lilly stated.
Most Read from Bloomberg Businessweek
© 2024 Bloomberg L.P.
